I am very confident in the efforts of our teams to obtain GBEA accreditation of our two GLPS service laboratories in molecular biology, both in Paris and in Gaithersburg, to serve biomedical research and our own medical diagnostics in neurodegenerative diseases and cancers. This is a crucial step for our revenues to grow as early as 2009. In addition, in 2008, we will have the results of over 5 years of ongoing efforts with our partners, Allergan and bioMerieux, and the new management will endeavour to translate these results in realistic operational and marketing ambitions."
Overview of ExonHit's business activities
In order to better organise its operations and to increase its chances of building its revenues, the Company has implemented two commercial departments: "Molecular Diagnostic/Genomic Services" and "Therapeutics".
Each department shall have the necessary resources to reach its objectives, as well as large autonomy to determine those objectives. The R&D, for each department, will conduct the research and reach the objectives that will have been set.
Of course, there will be the two departments will be connected and information shared. To this end, a Strategy department has been created, which aims at ensuring the coherence and the long term objectives of the Company. This department will include Operations and Project organisation.
For 2008, Operations will concentrate their efforts on obtaining an accreditation to realise clinical diagnostics in Paris and Gaithersburg. It will also realise the services which ExonHit offers its customers in biomedical research, and continue the promotion of its tools both in the US and in Europe.
In 2008, the Company will continue to invest in its two fields of
activity, both in partnership and in-house, in line with the projects
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved